Market Research Logo

Ocular Cancer Drug Development Pipeline Review, 2018

Ocular Cancer Drug Development Pipeline Review, 2018

Summary

Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity.

There are seven products in active development for this indication and companies operating in this space include Ophthotech and VCN Biosciences.

Uveal melanoma, the most common intraocular tumor, is a disease in which melanocytes, found in the part of the eye called the uvea, become cancerous. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. There are 35 products in active development for this indication and companies operating in this space include Novartis and Eli Lilly.

Molecular targets acted on by products in development for ocular cancer include tumor antigens, kinases and growth factor receptors.

This report “Ocular Cancer Drug Development Pipeline Review, 2018”provides an overview of the pipeline landscape for ocular cancer and comprehensive information on the therapeutics under development and key players involved in therapeutic development for retinoblastoma and uveal melanoma. It also features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Ocular Cancer Report Coverage
2.2 Retinoblastoma - Overview
2.3 Uveal Melanoma - Overview
3 Therapeutics Development
3.1 Retinoblastoma
3.2 Uveal Melanoma
4 Therapeutics Assessment
4.1 Retinoblastoma
4.2 Uveal Melanoma
5 Companies Involved in Therapeutics Development
5.1 Retinoblastoma
5.2 Uveal Melanoma
6 Dormant Projects
6.1 Retinoblastoma
6.2 Uveal Melanoma
7 Discontinued Products
7.1 Uveal Melanoma
8 Product Development Milestones
8.1 Retinoblastoma
8.2 Uveal Melanoma
9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer
1.1 List of Tables
Table 1: Number of Products under Development for Retinoblastoma
Table 2: Number of Products under Development by Companies, Retinoblastoma
Table 3: Products under Development by Companies, Retinoblastoma
Table 4: Number of Products under Development for Uveal Melanoma
Table 5: Number of Products under Development by Companies, Uveal Melanoma
Table 6: Number of Products under Development by Universities/Institutes, Uveal Melanoma
Table 7: Products under Development by Companies, Uveal Melanoma
Table 8: Products under Development by Universities/Institutes, Uveal Melanoma
Table 9: Number of Products by Stage and Target, Retinoblastoma
Table 10: Number of Products by Stage and Mechanism of Action, Retinoblastoma
Table 11: Number of Products by Stage and Route of Administration, Retinoblastoma
Table 12: Number of Products by Stage and Molecule Type, Retinoblastoma
Table 13: Number of Products by Stage and Target, Uveal Melanoma
Table 14: Number of Products by Stage and Mechanism of Action, Uveal Melanoma
Table 15: Number of Products by Stage and Route of Administration, Uveal Melanoma
Table 16: Number of Products by Stage and Molecule Type, Uveal Melanoma
Table 17: Retinoblastoma - Pipeline by APEIRON Biologics AG, H1 2018
Table 18: Retinoblastoma - Pipeline by EyePoint Pharmaceuticals Inc, H1 2018
Table 19: Retinoblastoma - Pipeline by Innovation Pharmaceuticals Inc, H1 2018
Table 20: Retinoblastoma - Pipeline by Ophthotech Corp, H1 2018
Table 21: Retinoblastoma - Pipeline by PepVax Inc, H1 2018
Table 22: Retinoblastoma - Pipeline by VCN Biosciences SL, H1 2018
Table 23: Uveal Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
Table 24: Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018
Table 25: Uveal Melanoma - Pipeline by Bristol-Myers Squibb Co, H1 2018
Table 26: Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2018
Table 27: Uveal Melanoma - Pipeline by Cleveland BioLabs Inc, H1 2018
Table 28: Uveal Melanoma - Pipeline by Delcath Systems Inc, H1 2018
Table 29: Uveal Melanoma - Pipeline by Eli Lilly and Co, H1 2018
Table 30: Uveal Melanoma - Pipeline by Iconic Therapeutics Inc, H1 2018
Table 31: Uveal Melanoma - Pipeline by Immunocore Ltd, H1 2018
Table 32: Uveal Melanoma - Pipeline by Iovance Biotherapeutics Inc, H1 2018
Table 33: Uveal Melanoma - Pipeline by Novartis AG, H1 2018
Table 34: Uveal Melanoma - Pipeline by PEP-Therapy SAS, H1 2018
Table 35: Uveal Melanoma - Pipeline by Pfizer Inc, H1 2018
Table 36: Uveal Melanoma - Pipeline by Plexxikon Inc, H1 2018
Table 37: Uveal Melanoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2018
Table 38: Uveal Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H1 2018
Table 39: Uveal Melanoma - Pipeline by Tesaro Inc, H1 2018
Table 40: Uveal Melanoma - Pipeline by Viralytics Ltd, H1 2018
Table 41: Retinoblastoma - Dormant Projects, H1 2018
Table 42: Uveal Melanoma - Dormant Projects, H1 2018
Table 43: Uveal Melanoma - Discontinued Products, H1 2018
1.2 List of Figures
Figure 1: Number of Products under Development for Retinoblastoma
Figure 2: Number of Products under Development by Companies, Retinoblastoma
Figure 3: Number of Products under Development for Uveal Melanoma
Figure 4: Number of Products under Development by Companies, Uveal Melanoma
Figure 5: Number of Products under Development by Universities/Institutes, Uveal Melanoma
Figure 6: Number of Products by Targets, Retinoblastoma
Figure 7: Number of Products by Stage and Targets, Retinoblastoma
Figure 8: Number of Products by Mechanism of Actions, Retinoblastoma
Figure 9: Number of Products by Stage and Mechanism of Actions, Retinoblastoma
Figure 10: Number of Products by Routes of Administration, Retinoblastoma
Figure 11: Number of Products by Stage and Routes of Administration, Retinoblastoma
Figure 12: Number of Products by Molecule Types, Retinoblastoma
Figure 13: Number of Products by Stage and Molecule Types, Retinoblastoma
Figure 14: Number of Products by Top 10 Targets, Uveal Melanoma
Figure 15: Number of Products by Stage and Top 10 Targets, Uveal Melanoma
Figure 16: Number of Products by Top 10 Mechanism of Actions, Uveal Melanoma
Figure 17: Number of Products by Stage and Top 10 Mechanism of Actions, Uveal Melanoma
Figure 18: Number of Products by Routes of Administration, Uveal Melanoma
Figure 19: Number of Products by Stage and Routes of Administration, Uveal Melanoma
Figure 20: Number of Products by Top 10 Molecule Types, Uveal Melanoma
Figure 21: Number of Products by Stage and Top 10 Molecule Types, Uveal Melanoma

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report